LifeMD Q2 revenue $47.3M, adjusted EBITDA loss $3.5M; revises FY2026 guidance

LifeMD, Inc.

Revenue $47.3M within guidance; adjusted EBITDA loss $3.5M improved 21% sequentially but below guided range.
Gross margin expanded ~280 bps YoY to ~89%; total active subscribers up 20% YoY to ~356k.
Weight management subscribers ~108k; ~95% of new weight patients start on branded GLP-1 therapies.
Launched telehealth co-marketing with Halozyme's Antares for XYOSTED; expects $2-3M net launch costs in 2026.
Revises FY2026 guidance: revenue $205.5M-$212.5M, adjusted EBITDA -$6M to breakeven; expects positive adjusted EBITDA in H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.